Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MD, is a Professor of Genitourinary Oncology and Director at Barts Cancer Centre at St. Bartholomew’s Hospital in London, UK, as well as Lead for Solid Tumour Research. Dr. Powles also serves as co-host of The Uromigos podcast.
Articles by Thomas Powles, MBBS, MRCP, MD
In part 3 of the session, the panel discusses the latest developments in treatments for papillary kidney cancer.
In the second part of the session, the panel highlights some of the most important recent developments in papillary RCC.
In part one of the session, the panelists dive into an in-depth exploration and debate on the results of SUNNIFORECAST.
In the final part of this session, the panel discusses the nuances of re-challenging patients with PD-1 therapies.
The panel discusses the use of immunotherapy, specifically PD-1 based therapies, in renal cell carcinoma.
Part two features a discussion on the timing and rationale behind conducting trials for re-challenging patients.
The panelists discuss the use of immune checkpoint inhibitors and re-challenging patients with PD-1/PD-L1 therapies.
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
The panelists wrap up this peri-operative therapy session with what the envision for the future for sparing bladders.
In this third segment, the panelists discuss bladder-sparing approaches.
The second part of this four-part segment includes conversation about ctDNA in bladder cancer.
The first part of four segments from the panel session on peri-operative therapy in bladder cancer.
The NIAGARA study showed significant survival benefits with perioperative durvalumab for patients with MIBC.
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
View the live recording of the "The Uromigos' Definition of Oligometastatic" session from Uromigos Live 2024.
View the IO Rechallenge panel session from Uromigos Live & Unplugged 2024, recorded live in Nashville.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.